OSE Immunotherapeutics Issues Business and Corporate Update

OSE Immunotherapeutics has recently reinforced its strategic business model through new pharmaceutical partnerships, positioning itself for substantial growth and development in the coming years. The company has entered into three major agreements, each set to bolster its innovative therapeutic pipeline and expand its reach in both immuno-oncology and immuno-inflammation.

In the last three months, OSE Immunotherapeutics has forged a new partnership with AbbVie for the development of OSE-230, a pioneering preclinical program targeting chronic inflammation. Additionally, the company has extended its collaboration with Boehringer Ingelheim, amending the existing licensing agreement on SIRPα compounds to now include cardiovascular-renal-metabolic diseases, with Phase 2 trials anticipated later this year. Moreover, the acquisition of a preclinical program from OSE’s cis-targeting anti-PD1/cytokine platform marks another significant step forward.

Financially, OSE Immunotherapeutics is well-positioned to support its strategic initiatives through to 2027. This stability is bolstered by recent funding from the 'France 2030' public initiative, which aids the pivotal Phase 3 clinical trial of Tedopi® in lung cancer. Additionally, new international executives will join the Board of Directors, bringing valuable expertise that will enhance the company’s global presence and strategic decision-making.

Nicolas Poirier, CEO of OSE Immunotherapeutics, highlighted the significance of these partnerships and the company's innovative immunological pipeline. He emphasized that these agreements have strengthened their business model, allowing for the development of late-stage, first-in-class clinical products. Poirier expressed optimism for the milestones anticipated in 2024, particularly in advancing their proprietary and partnered assets such as the anti-IL-7R monoclonal antibody Lusvertikimab in Phase 2 for Ulcerative Colitis and the cancer vaccine Tedopi® in a pivotal Phase 3 trial for Non-Small Cell Lung Cancer.

Chairwoman Dominique Costantini also reflected on the company’s rapid progress over the past few years. She noted the development of a robust and diverse portfolio of drug candidates, both proprietary and in collaboration with leading pharmaceutical companies. Costantini asserted that 2024 is set to be a transformative year, with the potential for OSE Immunotherapeutics to become a key player in the European biotechnology sector.

OSE Immunotherapeutics is set to propose the addition of four new independent directors at the upcoming General Shareholders’ meeting. These appointments aim to further strengthen the company’s strategic and operational capabilities. The proposed directors bring extensive experience in the life sciences, financial engineering, and market development, which will be crucial in navigating the company’s growth trajectory.

Strategically, OSE Immunotherapeutics has made significant announcements since early 2024. On February 28th, they entered into a partnership with AbbVie to develop OSE-230, receiving a $48 million upfront payment and potential additional milestones up to $665 million. On April 10th, they secured €8.4 million in public funding to support the Phase 3 trial of Tedopi® in lung cancer. Furthermore, on May 24th, they expanded their collaboration with Boehringer Ingelheim, receiving a total of €38.8 million, with potential additional milestones up to €1.1 billion.

OSE Immunotherapeutics continues to focus on developing first-in-class assets in immuno-oncology and immuno-inflammation. Their balanced clinical pipeline includes Tedopi®, OSE-279, OSE-127 (Lusvertikimab), FR-104/VEL-101, and the anti-SIRPα monoclonal antibody. These programs underscore their commitment to advancing innovative therapeutic solutions.

The company’s three proprietary drug discovery platforms—Pro-resolutive mAb, Myeloid Checkpoint, and BiCKI®—remain central to their mission of delivering next-generation immunotherapies. Each platform is designed to optimize therapeutic potential, targeting specific pathways in inflammation resolution and immune regulation.

OSE Immunotherapeutics is poised for a transformative year, aiming to make significant strides in the biotech industry through strategic partnerships, innovative drug development, and a strengthened leadership team.